trial

Glycine Treatment of Prodromal Symptoms

NCTId NCT00268749
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 10 (actual)
Sponsored by Yale University
Primary completion 2004-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
10 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2002-07
Primary completion
2004-11
Eligibility
ALL · 14 Years · 35 Years

Interventions & indications

Drugs
glycine

Sponsors

Yale UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

0 total

Linked catalysts

1
Glycine Treatment of Prodromal Symptoms — primary completion2004-11

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE2
Primary Completion Date
2004-11
Status
COMPLETED
relationships
The graph out of here
drug
glycine
drug
lead_sponsor
Yale University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Scott W. Woods, MD
person